AnewPharma
14
0
0
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 14 trials
100.0%
+13.5% vs industry average
7%
1 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors
Role: lead
The Absorption, Metabolism and Excretion of [14C]CM082 in Human
Role: lead
Bioequivalency Study of CM082 Tablet in Healthy Volunteers
Role: lead
CM082 in Patients With Myopic Choroidal Neovascularization (CNV)
Role: lead
CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma
Role: lead
CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).
Role: lead
CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC)
Role: lead
A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy Volunteers
Role: lead
Safety and Tolerability of Oral CM082 in Patients With wAMD
Role: lead
Phase 1 Study of CM082 in Patients With wAMD
Role: lead
Phase 1 Study of CM082 (X-82) Tablets in Advanced Cancer Patients in China
Role: lead
Study of the Combination of CM082 With JS001 in Patients With Advanced Mucosal Melanoma.
Role: lead
Second-line CM082 Combined With Paclitaxel For Patients With Advanced Gastric Cancer
Role: lead
Study of the Combination of CM082 With Everolimus in Patients With mRCC
Role: lead
All 14 trials loaded